tiprankstipranks
Tvardi Therapeutics Inc. (TVRD)
NASDAQ:TVRD
US Market
TVRD
Tvardi Therapeutics
RESEARCH TOOLSreports
Want to see TVRD full AI Analyst Report?

Tvardi Therapeutics (TVRD) Earnings Dates, Call Summary & Reports

2,524 Followers

Earnings Data

Report Date
Aug 13, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.7
Last Year’s EPS
-1
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 8 Analysts Ratings

Earnings Call Summary

Q4 2023
Earnings Call Date:Mar 04, 2024|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call highlighted a strategic focus on a promising NP program with potential for significant clinical and commercial success. However, challenges with KORSUVA revenue and increased R&D expenses were notable concerns.
Company Guidance
In the earnings call for Cara Therapeutics, the company provided guidance focused on the development of oral difelikefalin for notalgia paresthetica (NP), prioritizing this program to extend their cash runway into 2026. They reported significant demand growth for KORSUVA injection, with a 22% increase in vial shipments in Q4 2023, although future revenue from KORSUVA is not expected to be substantial due to reimbursement changes. The company highlighted that 34 million U.S. adults suffer from chronic pruritus, with 650,000 diagnosed NP patients, noting the lack of approved therapies and the significant unmet need for effective treatment. The Phase II/III COURAGE I study for NP has completed enrollment ahead of schedule, with top-line results anticipated in Q3 2024. Financially, Cara reported $3 million in revenue for Q4 2023 and ended the year with $1.8 million in cash, cash equivalents, and marketable securities, after using $92.1 million in operating activities and securing $36.5 million from a financing transaction.
Focus on Notalgia Paresthetica
Cara Therapeutics has prioritized its program focusing on oral difelikefalin for notalgia paresthetica (NP), a chronic neuropathic condition with a significant unmet need. This strategic focus extends their cash runway into 2026.
Successful Phase II Study for NP
Phase II proof-of-concept study for oral difelikefalin showed statistically significant results in reducing itch in NP patients, with rapid enrollment in the Phase II/III COURAGE I study.
Strong Demand Growth for KORSUVA Injection
KORSUVA injection saw a 22% increase in demand quarter-to-quarter, reflecting its clinical benefit.
Financial Strategy Enhancements
Cara completed a financing transaction with Healthcare Royalty, bringing forward the value of ex-U.S. and Japan royalties in a nondilutive manner, strengthening their balance sheet.

Tvardi Therapeutics (TVRD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

TVRD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 13, 2026
2026 (Q2)
-0.70 / -
-1―――
May 08, 2026
2026 (Q1)
- / -
-3.22―――
Mar 31, 2026
2025 (Q4)
-0.74 / -0.73
-3.2277.33% (+2.49)――
Nov 13, 2025
2025 (Q3)
-1.00 / -0.59
-8.18992.80% (+7.60)――
Aug 14, 2025
2025 (Q2)
-0.68 / -1.00
-13.16792.41% (+12.17)――
May 13, 2025
2025 (Q1)
-0.58 / -3.22
-20.1684.03% (+16.94)――
Feb 26, 2025
2024 (Q4)
- / -1.68
-7.0876.27% (+5.40)――
Nov 04, 2024
2024 (Q3)
-0.24 / -0.23
-0.5256.15% (+0.29)――
Aug 05, 2024
2024 (Q2)
-0.27 / -0.27
-0.5853.45% (+0.31)――
May 13, 2024
2024 (Q1)
-14.33 / -20.16
-17.64-14.29% (-2.52)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

TVRD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 08, 2026
$4.21$4.18-0.71%
Mar 31, 2026
$3.18$3.00-5.66%
Nov 13, 2025
$4.11$4.03-1.95%
Aug 14, 2025
$23.79$24.00+0.88%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Tvardi Therapeutics Inc. (TVRD) report earnings?
Tvardi Therapeutics Inc. (TVRD) is schdueled to report earning on Aug 13, 2026, TBA (Confirmed).
    What is Tvardi Therapeutics Inc. (TVRD) earnings time?
    Tvardi Therapeutics Inc. (TVRD) earnings time is at Aug 13, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is TVRD EPS forecast?
          TVRD EPS forecast for the fiscal quarter 2026 (Q2) is -0.7.